Chenming Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chenming Guo has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Yiyang Wang
20 shared publicationsYongxiang Li
15 shared publicationsHaotian Ma
Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University
10 shared publicationsJiawei Zhao
9 shared publicationsDilimulati Ismtula
Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University
8 shared publicationsJunyi Wang
Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
5 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Scientific Reports
Pan-cancer expression and clinical associations of HSD11B2 and its functional role in breast cancer cells
- 10 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessPan-cancer expression and clinical associations of HSD11B2 and its functional role in breast cancer cells
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1999838
ABCF2 is a prognostic and immunological pan-cancer biomarker with growth-promoting function in breast cancer: a multi-omics study
Background: Unlike canonical members of the ABC transporter superfamily, ATP-binding cassette sub-family F member 2 (ABCF2) carries no transmembrane domains and participates in translational regulation. Nevertheless, its expression pattern, prognostic importance, genetic and epigenetic control, and immune-related effects have not been systematically evaluated across human malignancies, and its biological role and druggability in breast cancer remain unclear. We therefore combined multi-platform public omics data with in vitro and in vivo experiments to delineate the pan-cancer molecular features of ABCF2 and its impact on breast cancer malignant phenotypes. Methods: TCGA and GTEx transcriptomic and clinical data were combined to evaluate ABCF2 expression, diagnostic value, and prognostic relevance (OS, DSS, and PFI) across 33 cancer types; CPTAC and HPA data served for protein-level validation. Genetic alterations, promoter methylation, m6A regulator associations, genomic heterogeneity indicators (TMB, MSI, NEO, MATH, HRD, and LOH), immune infiltration (ESTIMATE, ssGSEA, and TIMER-based deconvolution), functional enrichment (GO, KEGG, and GSEA), and drug sensitivity (CTRP and GDSC) were analyzed, and prognostic nomograms were built and validated. In BRCA, 16 paired clinical tissues and cell lines served to verify ABCF2 expression, and loss- and gain-of-function experiments (CCK-8, colony formation, wound healing, Transwell) plus a subcutaneous xenograft model defined its biological role. Results: Most TCGA cancer types showed significant ABCF2 upregulation, and combined TCGA-GTEx analysis confirmed broad overexpression concordant at the protein level. High ABCF2 expression indicated poor OS in BRCA, GBM, LGG, LIHC, LUAD, and SKCM, acted as an independent prognostic factor in multiple cancers, and supported nomograms with modest-to-moderate discrimination; diagnostic accuracy exceeded an AUC of 0.9 in CHOL, COAD, LIHC, STAD, and THYM. ABCF2 overexpression was accompanied by gene amplification, promoter hypomethylation, and positive correlations with m6A regulators. Elevated ABCF2 coincided with an immunosuppressive milieu (less CD8+ T-cell infiltration, more Th2 cells and MDSCs, positive correlations with NECTIN2 and TGFB1). ABCF2-associated genes centered on ribosome biogenesis, DNA replication, and cell cycle, while high ABCF2 levels were associated with higher in silico IC50 estimates of several EGFR-targeted agents. In BRCA, silencing ABCF2 weakened malignant phenotypes in vitro and slowed xenograft growth in vivo , while overexpression produced the converse effects. Conclusion: ABCF2 is frequently upregulated across cancer types and is associated with prognostic, diagnostic, and immune-related features; functional experiments support a growth-promoting role in breast cancer and nominate it as a candidate for further translational investigation.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1999838
Open AccessABCF2 is a prognostic and immunological pan-cancer biomarker with growth-promoting function in breast cancer: a multi-omics study
Background: Unlike canonical members of the ABC transporter superfamily, ATP-binding cassette sub-family F member 2 (ABCF2) carries no transmembrane domains and participates in translational regulation. Nevertheless, its expression pattern, prognostic importance, genetic and epigenetic control, and immune-related effects have not been systematically evaluated across human malignancies, and its biological role and druggability in breast cancer remain unclear. We therefore combined multi-platform public omics data with in vitro and in vivo experiments to delineate the pan-cancer molecular features of ABCF2 and its impact on breast cancer malignant phenotypes. Methods: TCGA and GTEx transcriptomic and clinical data were combined to evaluate ABCF2 expression, diagnostic value, and prognostic relevance (OS, DSS, and PFI) across 33 cancer types; CPTAC and HPA data served for protein-level validation. Genetic alterations, promoter methylation, m6A regulator associations, genomic heterogeneity indicators (TMB, MSI, NEO, MATH, HRD, and LOH), immune infiltration (ESTIMATE, ssGSEA, and TIMER-based deconvolution), functional enrichment (GO, KEGG, and GSEA), and drug sensitivity (CTRP and GDSC) were analyzed, and prognostic nomograms were built and validated. In BRCA, 16 paired clinical tissues and cell lines served to verify ABCF2 expression, and loss- and gain-of-function experiments (CCK-8, colony formation, wound healing, Transwell) plus a subcutaneous xenograft model defined its biological role. Results: Most TCGA cancer types showed significant ABCF2 upregulation, and combined TCGA-GTEx analysis confirmed broad overexpression concordant at the protein level. High ABCF2 expression indicated poor OS in BRCA, GBM, LGG, LIHC, LUAD, and SKCM, acted as an independent prognostic factor in multiple cancers, and supported nomograms with modest-to-moderate discrimination; diagnostic accuracy exceeded an AUC of 0.9 in CHOL, COAD, LIHC, STAD, and THYM. ABCF2 overexpression was accompanied by gene amplification, promoter hypomethylation, and positive correlations with m6A regulators. Elevated ABCF2 coincided with an immunosuppressive milieu (less CD8+ T-cell infiltration, more Th2 cells and MDSCs, positive correlations with NECTIN2 and TGFB1). ABCF2-associated genes centered on ribosome biogenesis, DNA replication, and cell cycle, while high ABCF2 levels were associated with higher in silico IC50 estimates of several EGFR-targeted agents. In BRCA, silencing ABCF2 weakened malignant phenotypes in vitro and slowed xenograft growth in vivo , while overexpression produced the converse effects. Conclusion: ABCF2 is frequently upregulated across cancer types and is associated with prognostic, diagnostic, and immune-related features; functional experiments support a growth-promoting role in breast cancer and nominate it as a candidate for further translational investigation.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Development and External Validation of a Preoperative Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer Using Routine Ultrasound and Core Needle Biopsy Variables
Background: Accurate preoperative assessment of axillary lymph node metastasis (ALNM) is essential for individualized axillary management in breast cancer, yet imaging-based evaluation alone remains imperfect. We aimed to develop and externally validate a practical nomogram based on routinely available preoperative ultrasound and core needle biopsy (CNB) variables. Methods: This retrospective, two-center cohort study included 295 women with pathologically confirmed primary breast cancer who underwent breast surgery with axillary nodal staging between January 2021 and January 2025. The training cohort included 182 patients from the Changji Branch, and the external validation cohort included 113 patients from the First Affiliated Hospital of Xinjiang Medical University. Candidate predictors were evaluated using univariable analysis, LASSO regression, and multivariable logistic regression. Model discrimination, calibration, and clinical utility were assessed using receiver operating characteristic analysis, calibration analysis, and decision curve analysis. Results: ALNM was confirmed in 88 of 182 patients (48.4%) in the training cohort and 50 of 113 patients (44.2%) in the external validation cohort. The final nomogram included ultrasound-reported calcifications, tumor size, histological grade, CNB-derived lymphovascular invasion, and HER2 status. The model showed good discrimination, with an AUC of 0.858 (95% CI 0.805– 0.911) in the training cohort and 0.854 (95% CI 0.779– 0.929) in the external validation cohort. Calibration and decision curve analyses supported acceptable model performance and potential clinical utility in both cohorts. Conclusion: : We developed and externally validated an interpretable preoperative nomogram using routinely obtainable ultrasound and CNB variables for individualized estimation of ALNM risk in breast cancer. The model may support preoperative risk stratification and axillary management planning, although prospective multicenter validation is warranted.
- 1 September 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Open AccessDevelopment and External Validation of a Preoperative Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer Using Routine Ultrasound and Core Needle Biopsy Variables
Background: Accurate preoperative assessment of axillary lymph node metastasis (ALNM) is essential for individualized axillary management in breast cancer, yet imaging-based evaluation alone remains imperfect. We aimed to develop and externally validate a practical nomogram based on routinely available preoperative ultrasound and core needle biopsy (CNB) variables. Methods: This retrospective, two-center cohort study included 295 women with pathologically confirmed primary breast cancer who underwent breast surgery with axillary nodal staging between January 2021 and January 2025. The training cohort included 182 patients from the Changji Branch, and the external validation cohort included 113 patients from the First Affiliated Hospital of Xinjiang Medical University. Candidate predictors were evaluated using univariable analysis, LASSO regression, and multivariable logistic regression. Model discrimination, calibration, and clinical utility were assessed using receiver operating characteristic analysis, calibration analysis, and decision curve analysis. Results: ALNM was confirmed in 88 of 182 patients (48.4%) in the training cohort and 50 of 113 patients (44.2%) in the external validation cohort. The final nomogram included ultrasound-reported calcifications, tumor size, histological grade, CNB-derived lymphovascular invasion, and HER2 status. The model showed good discrimination, with an AUC of 0.858 (95% CI 0.805– 0.911) in the training cohort and 0.854 (95% CI 0.779– 0.929) in the external validation cohort. Calibration and decision curve analyses supported acceptable model performance and potential clinical utility in both cohorts. Conclusion: : We developed and externally validated an interpretable preoperative nomogram using routinely obtainable ultrasound and CNB variables for individualized estimation of ALNM risk in breast cancer. The model may support preoperative risk stratification and axillary management planning, although prospective multicenter validation is warranted.
- Open Access
- 30 August 2026
- Published by Springer Nature in Scientific Reports
Multi-cancer profiling and breast cancer validation reveal YME1L1 as a potential immune-related factor and prognostic biomarker
- 30 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessMulti-cancer profiling and breast cancer validation reveal YME1L1 as a potential immune-related factor and prognostic biomarker
- Open Access
- 27 August 2026
- Published by Springer Nature in Scientific Reports
CLPTM1L is a prognostic and immune biomarker across human cancers validated in breast cancer
- 27 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessCLPTM1L is a prognostic and immune biomarker across human cancers validated in breast cancer
- Open Access
- 27 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integrative multi-omics characterization of HECTD3 across pan-cancer and its functional validation in thyroid cancer
- 27 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegrative multi-omics characterization of HECTD3 across pan-cancer and its functional validation in thyroid cancer
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1850798
UBTD1: a prognostic and immune biomarker validated in thyroid cancer and pan-cancer analysis
Background: Ubiquitin domain containing 1 (UBTD1), a molecule intimately associated with tumorigenesis and progression, is seen as a possible cancer therapy target. However, its diagnostic value, prognostic significance, and immunomodulatory functions of UBTD1 across cancers and in thyroid carcinoma have not yet been fully elucidated. Methods: Based on TCGA and other public database resources, this research carried out an extensive examination of the expression levels, prognostic potential, diagnostic value, epigenetic modifications, methylation status, immune significance, and pathway regulation of UBTD1, to explore its biological function in diverse malignant tumors. In addition, through in vitro experiments such as CCK-8, colony formation, transwell, and oris assays, as well as in vivo models of nude mouse xenografts, we validated the expression and regulatory function of UBTD1 in thyroid cancer. Results: The study indicates that the overexpression of UBTD1 is prevalent in many cancers and correlates with poor prognosis. UBTD1 is effective to a moderate or strong degree in identifying cancerous tissues compared to healthy ones, and it serves as an independent prognostic factor in ACC, LIHC, READ, and THCA patients. UBTD1 mutations are prevalent across various malignancies and correlate with patient prognosis. In the majority of malignancies, UBTD1 expression is positively associated with m6A methylation, showing increased methylation in its promoter region. Moreover, experiments demonstrated that UBTD1 overexpression reduces THCA cell proliferation, invasion, and migration, whereas its under expression exhibited the opposite biological effects. Conclusion: UBTD1 can be used as a biomarker of important clinical value in pan-cancer. Concurrently, this research clarified the expression and role of UBTD1 in THCA. These findings open new avenues for developing tumor treatments targeting UBTD1.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1850798
Open AccessUBTD1: a prognostic and immune biomarker validated in thyroid cancer and pan-cancer analysis
Background: Ubiquitin domain containing 1 (UBTD1), a molecule intimately associated with tumorigenesis and progression, is seen as a possible cancer therapy target. However, its diagnostic value, prognostic significance, and immunomodulatory functions of UBTD1 across cancers and in thyroid carcinoma have not yet been fully elucidated. Methods: Based on TCGA and other public database resources, this research carried out an extensive examination of the expression levels, prognostic potential, diagnostic value, epigenetic modifications, methylation status, immune significance, and pathway regulation of UBTD1, to explore its biological function in diverse malignant tumors. In addition, through in vitro experiments such as CCK-8, colony formation, transwell, and oris assays, as well as in vivo models of nude mouse xenografts, we validated the expression and regulatory function of UBTD1 in thyroid cancer. Results: The study indicates that the overexpression of UBTD1 is prevalent in many cancers and correlates with poor prognosis. UBTD1 is effective to a moderate or strong degree in identifying cancerous tissues compared to healthy ones, and it serves as an independent prognostic factor in ACC, LIHC, READ, and THCA patients. UBTD1 mutations are prevalent across various malignancies and correlate with patient prognosis. In the majority of malignancies, UBTD1 expression is positively associated with m6A methylation, showing increased methylation in its promoter region. Moreover, experiments demonstrated that UBTD1 overexpression reduces THCA cell proliferation, invasion, and migration, whereas its under expression exhibited the opposite biological effects. Conclusion: UBTD1 can be used as a biomarker of important clinical value in pan-cancer. Concurrently, this research clarified the expression and role of UBTD1 in THCA. These findings open new avenues for developing tumor treatments targeting UBTD1.
- Open Access
- 13 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integrated pan cancer analysis with breast cancer validation identifies SEC13 homolog as prognostic biomarker and immunotherapy target
As the core scaffold of the GAP Activity Toward Rags 2 complex (GATOR2) complex, SEC13 regulates mTORC1 signaling and endoplasmic reticulum homeostasis to modulate cellular metabolism, exhibits elevated expression across various solid tumors driving malignant progression, yet its comprehensive molecular mechanisms and immunotherapeutic potential remain to be systematically elucidated. We conducted a comprehensive cancer analysis of SEC13 using the TCGA and GEO databases to assess its expression, diagnostic importance, and prognostic relevance in different tumor types. We further investigated its genetic alterations, methylation modifications, and correlations with the immune microenvironment, and predicted potential molecular pathways through enrichment analysis. Specifically in breast cancer (BRCA), we validated SEC13 protein expression levels in tumor tissues by Western blotting; comprehensively analyzed the effects of SEC13 on BRCA cell proliferation, invasion, and migration capabilities using CCK-8, Transwell invasion, and cell scratch assays; and performed final validation at the protein level using tissue microarrays combined with immunohistochemistry. SEC13 was significantly overexpressed across the majority of tumor types relative to matched normal tissues and exhibited stage-specific expression patterns. Furthermore, SEC13 demonstrated substantial diagnostic potential in multiple malignancies; notably, its elevated expression served as an independent prognostic biomarker for breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and sarcoma (SARC). Bioinformatics analysis revealed that SEC13 mutations were widely distributed across pan-cancer datasets and correlated with prognosis. Notably, SEC13 expression positively correlated with m6A methylation while its promoter region showed hypomethylation. Furthermore, high SEC13 expression was positively associated with immunogenomic markers but accompanied by a low immune infiltration phenotype. Functional experiments confirmed that SEC13 enhances cell proliferation, invasion, and migration in BRCA. This study, through comprehensive bioinformatics integration and functional validation in BRCA, suggests that SEC13 expression was correlated with tumor epigenetic modification-related processes (including m6A methylation and promoter DNA methylation) and immune microenvironment homeostasis in multiple malignancies, which provided correlative evidence for the potential involvement of SEC13 in tumor epigenetic and immune regulation. Its expression profile may serve as a potential pan-cancer prognostic indicator for molecular stratification and prognostic evaluation, providing preliminary exploratory insights for subsequent research on SEC13-related tumor regulatory mechanisms. Notably, the current in vivo validation using NCG immunodeficient mice focuses on tumor cell-intrinsic malignant phenotypes, and direct verification of immune regulatory effects requires follow-up experiments in immunocompetent or humanized mouse models.
- 13 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegrated pan cancer analysis with breast cancer validation identifies SEC13 homolog as prognostic biomarker and immunotherapy target
As the core scaffold of the GAP Activity Toward Rags 2 complex (GATOR2) complex, SEC13 regulates mTORC1 signaling and endoplasmic reticulum homeostasis to modulate cellular metabolism, exhibits elevated expression across various solid tumors driving malignant progression, yet its comprehensive molecular mechanisms and immunotherapeutic potential remain to be systematically elucidated. We conducted a comprehensive cancer analysis of SEC13 using the TCGA and GEO databases to assess its expression, diagnostic importance, and prognostic relevance in different tumor types. We further investigated its genetic alterations, methylation modifications, and correlations with the immune microenvironment, and predicted potential molecular pathways through enrichment analysis. Specifically in breast cancer (BRCA), we validated SEC13 protein expression levels in tumor tissues by Western blotting; comprehensively analyzed the effects of SEC13 on BRCA cell proliferation, invasion, and migration capabilities using CCK-8, Transwell invasion, and cell scratch assays; and performed final validation at the protein level using tissue microarrays combined with immunohistochemistry. SEC13 was significantly overexpressed across the majority of tumor types relative to matched normal tissues and exhibited stage-specific expression patterns. Furthermore, SEC13 demonstrated substantial diagnostic potential in multiple malignancies; notably, its elevated expression served as an independent prognostic biomarker for breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and sarcoma (SARC). Bioinformatics analysis revealed that SEC13 mutations were widely distributed across pan-cancer datasets and correlated with prognosis. Notably, SEC13 expression positively correlated with m6A methylation while its promoter region showed hypomethylation. Furthermore, high SEC13 expression was positively associated with immunogenomic markers but accompanied by a low immune infiltration phenotype. Functional experiments confirmed that SEC13 enhances cell proliferation, invasion, and migration in BRCA. This study, through comprehensive bioinformatics integration and functional validation in BRCA, suggests that SEC13 expression was correlated with tumor epigenetic modification-related processes (including m6A methylation and promoter DNA methylation) and immune microenvironment homeostasis in multiple malignancies, which provided correlative evidence for the potential involvement of SEC13 in tumor epigenetic and immune regulation. Its expression profile may serve as a potential pan-cancer prognostic indicator for molecular stratification and prognostic evaluation, providing preliminary exploratory insights for subsequent research on SEC13-related tumor regulatory mechanisms. Notably, the current in vivo validation using NCG immunodeficient mice focuses on tumor cell-intrinsic malignant phenotypes, and direct verification of immune regulatory effects requires follow-up experiments in immunocompetent or humanized mouse models.
- Open Access
- 15 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Pan-cancer analysis and breast cancer validation reveal DEAD-box helicase 23 as a crucial prognostic and immuno-biomarker
Abnormal RNA metabolism is one of the core mechanisms in tumorigenesis. DDX23, a member of the family of DEAD-box protein, characterized as an ATP-dependent RNA helicase, facilitates cancer progression due to its abnormal expression. However, systematic studies examining DDX23 across the pan-cancer spectrum remain scarce. We utilized databases like TCGA and GEO to thoroughly examine the expression pattern of DDX23 in our study, its prognostic value, diagnostic efficacy, and immune-related properties across multiple cancers. We foresee possible regulatory routes by building a network of protein interactions and performing analysis of functional enrichment. Concurrently, we validate the core biological functions of DDX23 through in vitro experiments. DDX23 demonstrates markedly increased expression across a majority types of cancer, and its overexpression is strongly tied to a negative patient outcome. The level of DDX23 expression is closely linked to tumor mutational burden and the presence of infiltrating immune cells. Functional enrichment analysis indicates that DDX23 primarily participates in pathways related to RNA splicing and cell proliferation. In breast cancer (BRCA) tissue, DDX23 expression is notably higher than in normal breast tissue. In vitro experiments provide additional confirmation that DDX23 substantially boosts breast cancer cells’ ability to proliferate, invade, and migrate. In this investigation, DDX23 has been identified as a crucial biological marker for forecasting survival outcomes and immunological overview in patients with various types of cancer. It clarifies its specific expression pattern and oncogenic function in BRCA, providing crucial evidence for its clinical application in BRCA-targeted therapy and highlighting its translational potential.
- 15 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPan-cancer analysis and breast cancer validation reveal DEAD-box helicase 23 as a crucial prognostic and immuno-biomarker
Abnormal RNA metabolism is one of the core mechanisms in tumorigenesis. DDX23, a member of the family of DEAD-box protein, characterized as an ATP-dependent RNA helicase, facilitates cancer progression due to its abnormal expression. However, systematic studies examining DDX23 across the pan-cancer spectrum remain scarce. We utilized databases like TCGA and GEO to thoroughly examine the expression pattern of DDX23 in our study, its prognostic value, diagnostic efficacy, and immune-related properties across multiple cancers. We foresee possible regulatory routes by building a network of protein interactions and performing analysis of functional enrichment. Concurrently, we validate the core biological functions of DDX23 through in vitro experiments. DDX23 demonstrates markedly increased expression across a majority types of cancer, and its overexpression is strongly tied to a negative patient outcome. The level of DDX23 expression is closely linked to tumor mutational burden and the presence of infiltrating immune cells. Functional enrichment analysis indicates that DDX23 primarily participates in pathways related to RNA splicing and cell proliferation. In breast cancer (BRCA) tissue, DDX23 expression is notably higher than in normal breast tissue. In vitro experiments provide additional confirmation that DDX23 substantially boosts breast cancer cells’ ability to proliferate, invade, and migrate. In this investigation, DDX23 has been identified as a crucial biological marker for forecasting survival outcomes and immunological overview in patients with various types of cancer. It clarifies its specific expression pattern and oncogenic function in BRCA, providing crucial evidence for its clinical application in BRCA-targeted therapy and highlighting its translational potential.